ABOUT THE EVENT

"This meeting offers both excellent networking opportunities as well as a chance to stay on top of developments in the field.”

Principal Scientist II, Novartis
 

"Close exchange with colleagues from pharma and leading academics. I really appreciated that there was enough time for networking and discussion. Discussion after the talks had enough time and went deep in content.”

Global Therapeutic Area Head Retinal Health, Boehringer Ingelheim
 

"Advanced imaging and identification of biomarkers for disease progression and evaluation of therapeutic efficacy are timely for the transformational therapies in horizon for retinal disease.”

Chief Scientific Officer, Nanoscope Therapeutics
 

"Overall, the event was very well organized with sharp focus and emphasis on a few specific areas in retinal diseases clinical trials and treatment. Since it was a small and focused gathering, it was easy to network.”

Chief Technology Officer, Forus Health
 

"Very high-quality discussion with industry-wide implications and the willingness for further collaboration.”

Director, Product Development, Abeona Therapeutics